Two-dose vaccine focuses on prevention during the critical dry-off phase in dairy cattle

Boehringer Ingelheim is strengthening its livestock health portfolio with the launch of LENZELTA, a new vaccine aimed at reducing the incidence and severity of clinical mastitis in dairy cattle—one of the most persistent and costly diseases in global dairy farming.

The vaccine, which will roll out across multiple European Union markets starting April 2026, targets two of the most significant mastitis-causing pathogens—Staphylococcus aureus and Escherichia coli—and is designed to support preventive herd health management during the critical dry-off period.

Tackling a High-Cost Dairy Challenge

Mastitis remains a major economic and operational burden for dairy farms worldwide, impacting milk yield, quality, and overall herd productivity. The disease is particularly disruptive around calving, when cows are most vulnerable, making preventive strategies a key focus area for both farmers and veterinarians.

By introducing LENZELTA, Boehringer Ingelheim is positioning itself deeper into the preventive care segment—an area gaining traction as producers seek to reduce antibiotic use, improve animal welfare, and stabilize production outcomes.

A Preventive, Program-Based Approach

LENZELTA is administered in two doses during the dry-off phase, allowing it to integrate into existing herd management routines. The vaccine offers early onset immunity and protection lasting up to six months, covering the period of highest susceptibility.

Its oil-free adjuvant formulation and flexible vial sizes are designed to simplify handling and improve adoption at the farm level—an important factor in large-scale dairy operations.

Shifting Toward Prevention in Animal Health

The launch reflects a broader shift in livestock management—from reactive treatment toward preventive, system-based health strategies. Vaccines such as LENZELTA are increasingly being used not just to control disease outbreaks, but to improve consistency in milk production and reduce long-term costs.

For veterinarians, the product adds a targeted tool for proactive mastitis control. For farmers, it offers a pathway to more predictable herd performance and reduced production losses.

Strategic Portfolio Expansion

With LENZELTA, Boehringer Ingelheim is expanding its mastitis portfolio at a time when dairy producers globally are under pressure to improve efficiency while meeting rising standards for sustainability and animal care.

As dairy systems evolve, innovations that combine ease of use with measurable health and productivity outcomes are likely to play a defining role—and vaccines are emerging as a central pillar in that transition.